Controlled-released buccoadhesive tablets of verapamil hydrochloride (VH) were obtained by incorporation of VH in suitable carrier systems standardised based on bioadhesion and dissolution. The carrier systems were formulated using carbomor 974P (CP974P) and hydroxypropylmethylcellulose (HPMC) or sodium carboxymethyl cellulose (NaCMC) or sodium alginate or guar gum as the bioadehsives. Mannitol and polyethylene glycol 6000 (PEG6000) were used as solubilizers singly or in combination. The effect of polymer concentration on the release profile and in-vitro bioadhesion of the matrix tablets was studied. Tablet formulations with carbomor 974P (5%), in combination with sodium alginate (20%) or HPMC (20%) showed 98% or 79% drug release, respectively after 6 h. The dissolution rate of the drug decreased by increasing CP974P concentration. Controlled-release buccoadhesive tablets containing VH were prepared and evaluated in order to achieve constant plasma concentrations during treatment of chronic hypertension and to improve the bioavailability of VH by the avoidance of hepatic first-pass metabolism. Pharmacological parameters and plasma concentration time curves obtained following buccal administration to rabbits of buccoadhesive tablets showed evidence of sustained release of VH. Bioavailability of VH was approximately two times that achieved after oral administraion of commercial tablets. The formulations were compared using pharmacokinetic parameters such as AUC, C max and T max values.
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INTRODUCTION
Verapamil is a phenylalkylamine calcium antagonist that inhibits the inward movement of calcium into cardiomyocytes and smooth muscle cells. 1 It is used in the treatment of supraventicular arrhythmias, angina and hypertension. 1, 2 Over 90% of verapamil is absorbed following oral administration with peak plasma concentrations occurring between 1 and 2 hours. Verapamil is subjected to a very considerable first-pass metabolism in the liver with upto 80% of the dose eliminated in this way. The bioavailability is therefore 20%, 3 and is susceptible to large inter-and intraindividual variation. 4 Sustained-release oral preparations are available for the treatment of angina and hypertension. 5, 6 VH acts within 5 min of intravenous administration and in about 1-2 h. after oral adminsitration. 7, 8 Bioavailability of hepatically metabolized drugs such as steroids can be substantially improved by buccal or sublingual dosing, because when administered by these routes, the drug is not exposed too quickly to the metabolic enzymes of the stomach and the liver during absorption. [9] [10] [11] On contact with the buccal mucosa, the drug permeates across the mucosal tissue to reach the systemic circulation.
The buccal mucosa has an expanse to smooth and relatively immobile surface for placement of dosage forms. The introduction of the concept of bioadhesion in drug delivery now permits precise localisation of dosage forms on the mucosal surface. 12 Mucoadhesive systems have generally been investigated as plateforms for controlled drug delivery. 13, 14 In this article, an attempt has been made to develop verapamil HCl buccal adhesive tablets to avoid the gastric degradation and first-pass metabolism in the liver. Verapamil HCl bioavailability in rabbits from CP974P / sodium alginate buccal adhesive tablets has been compared to the bioavailability of commercial drug tablets and verapamil HCl I.V injection.
The buccoadhesive formulations were investigated for their physicochemical properties such as bioadhesive forces, interaction between drug and different polymers by IR and DSC and in-vitro release of drug.
MATERIALS AND METHODS

Materials
Verapamil hydrochloride, VH (Sigma, USA), Diltiazem HCl (Sigma Chemical Co., St. Louis MO., USA), carbopol 974P (CP974), hydroxypyropylmethyl cellulose (HPMC) (Morgan Chemical Co., Egypt), sodium carboxymethyl cellulose (NaCMC) (Arabic Laboratory Equipment Co., Egypt), Guar gum (Sigma Chemical Co., Germany), polyethyleneglycol 6000 (PEG600) (Ubichem Ltd., Germany), mannitol BP80 (El-Gomhouria Co., Egypt) and sodium alginate (The General Chemical, Pharmaceutical Co., Ltd., England) and isoptin tablets and isoptin ampoule (El-Arabia Pharmaceutical Co., Egypt). The following chemicals and solvents were of chromatographic grade: Acetonitrile, methanol, N-hexnae (BDH Laboratory Supplies, England) and trifluoroacetic acid (Merck Co., Germany). All other chemicals used were of analytical grade.
Methods
Preparation of verapamil HCl buccoadhesive tablets
Verapamil HCl (VH) buccoadhesive tablets, 13 mm in diameter and with a hardness of 5-8 kg, were prepared by mixing 40 mg VH with 160 mg other ingredients, such as bioadhesive polymers and suitable excipients, and triturating in a morter. Tablets (200 mg) were compressed on a Carver® press at a force of 3 tons for 25 s using 13/32 flat-faced punches. These tablets were stored in a desiccator until further used. Two different polymers, CP974 with either one of the following HPMC or NaCMC or sodium alginate or guar gum were used. The various formulations prepared containing different weights of polymers and other excipients are listed in Table 1 .
Differential scanning calorimetric (DSC) studies
The DSC patterns of VH alone, excipients alone as well as 1:1 (w/w) physical mixtures of the drug and investigated excipients, were recorded using a Shimadzu model DSC-50 at scanning rate of 10°/min from 30° to 350°u nder nitrogen gas stream at a flow rate of 40 ml/min. Samples of 5 mg were accurately weighed and encapsulated into a liquid sample pan.
Infrared absorption spectroscopy (IR)
The IR spectra were obtained with an IR-470 infrared spectrophotometer (Shimadzu, Japan) using KBr disk method. The disks were made under a pressure equal to 400 kg/cm 2 . 
In-vitro mucoadhesion study
To investigate how well the tablets would adhere to the buccal mucosa, mucoadhesion of the tablets was measured using a previously published method 15 using bovine intestine as a model mucosal membrane. Fresh bovine intestine obtained at slaughter was rapidly frozen to -20°. Before use a circular piece (2 cm 2 ) of membrane was cut and brought to room temperature in saline solution, then glued with cyanoacrylate adhesive on the ground surface of a tissue holder made of plexiglas. Similarly, the tablet was glued to another holder of the same size. Thereafter, the mucosal membrane was first blotted with a filter paper and then moistened with 25 ul of phosphate buffer pH 6.8. The tablet was kept in contact with mucosal membrane for 5 min after which, water was added to the polypropylene bag through an intravenous infusion set at constant rate of one drop/sec. until the tablet detached from the tissue. The water collected in the bag was measured and expressed as weight (g) required for detachment.
Swelling studies of buccoadhesive tablets
In this study, three tablets for each formulation were placed in a petri dish containing 50 ml of phosphate buffer pH 6.8 maintained at 37.0°. The tablets were removed at time intervals of 0.5, 1, 2, 3, 4, 5 and 6 h. Excess water on the surface of the tablets were carfully absorbed using filter paper, and swollen tablets were weighed and the changes of the volume were measured. The diameter and thickness of the tablets were measured using a micrometer. The volume of each tablet was calculated using the following formula: volume = π.d 2 .t. where π= 3.14, d is the diameter of the tablet and t is the thickness of the tablet.
Normalized swelling values were calculated from either normalized swelling volume or normalized swelling weight. 16
In-vitro drug release studies
The drug release from the buccal tablets was performed using USP XXIII apparatus 2 (Paddle method) using phosphate buffer (250 ml, pH 6.8) as dissolution medium, which was maintained at 37° and stirred at 50 rpm. Each tablet was fixed at a glass slide so that the drug could be released only from the upper surface. Aliquots (5 ml each) were withdrawn after 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 360 min with aid of pipette, the drug content was determined spectrophotometrically at λ max 230 nm.
In-vivo evaluation of buccal tablets
Six healthy albino rabbits weighing 1.8-2 kg were used as experimental animals in this study. The rabbits were fasted overnight before the administration of the dosage forms. During all experiments, water ad libitum was available and load given 6 h after the dose was administered. There was a washout period of 1week prior to in-vivo evaluation of the next formulation.
Intravenous dosing
Intravenous dosing (0.625 mg/kg body weight) was performed using isoptin ampoule (2.5 mg/ml) (N.B. The dose decreased in this case to prevent cardiac arrest of rabbit which may lead to death).
Buccal dosing
For buccal dosing, the rabbits were first anesthetized with an urethane and maintained on urethane for 2 h to allow adhesion of the tablets to the buccal mucosa. Tablets containing 40 mg VH (F 22 from Table 1 ) were cut in five. Each fifth was attached to the buccal mucosa of rabbit by pressing it for 30 sec. Blood samples (2 ml) were withdrawn just before dosing (blank plasma), and at 5, 15, 30, 60, 90, 120, 150, 180, 240, 300, 360, 420 and 480 min from the middle ear vein using a 26gauge needle and syringe and were collected in heparinized vials and stored at -20° until assayed.
Plasma was obtained via centrifugation and stored at -10° until assayed by HPLC as described below.
Oral dosing
Each rabbit was dosed with commercially available VH tablet after grinding it and making an aqueous suspension. 3 mg/kg VH from the previously prepared suspension were administered orally to rabbits through an intragastric tube, and blood samples were collected and stored as above.
Assay of verapamil HCl in plasma
The analytical method of Watson and Kapur 17 with some modifications was used to determine verapamil HCl in plasma as follows: To 500 µl plasma, (containing 0.02 µg of diltiazem HCl as an internal standard), 5 ml of n-hexane were added and vortex mixed. The samples were alkalinized with 0.1 ml sodium hydroxide (2 M), then centrifuged at 3000 rpm for 15 min. The organic layer was transferred to a conical tube and 100 µl of mobile phase consisting of acetonitrile / 0.1 M phosphate buffer (40:60) was added. The contents were mixed via vortex for 2 min and centrifuged at 3000 rpm for 15 min. Aliquots of 20 µl of aqueous layer were injected onto a C18 column (Lichrosorb C18 RP-column 250x4.6 mm L.D). A flow rate of 1 ml/min (Knauer-Ministar K-500 pump) was used for the mobile phase consisting of 0.1 M pH 3 phosphate buffer / acetonitrile (60:40 parts). VH and diltiazem (the internal standard) were detected at a wavelength of 230 nm, using a UV detecter (Knauer UV-Vis detector K2500 spectrophotometer). Chromatograms were recorded and analyzed using Shimdazu Chromatopac C-R6A integrator Inc. Osaka, Japan. Standard curves were developed in plasma for the VH within a range of 100 to 2000 ng/ml. The peak area was plotted as a function of VH concentration. The linearity of the method (r > 0.999) was determined to show a directly proportional relationship between the peak response and the concentration of VH. All experiments were run as triplicates and the mean values ±SD were taken.
Pharmacokinetic analysis
Parameters including AUC, C max and time to reach maximum plasma concentration T max were estimated from the plasma concentrationtime profiles. The area under the plasma concentration-time curve (AUC) from t= 0 h to the time of the last blood sample (t= 8 h) was determined by the linear trapezoidal rule. The AUC values obtained for the various formulations were normalized to 3 mg/kg (I.V. dose) of rabbit weight using the following formula described by Jain et al. 18 (mg) dose Actual
The normalization of the data was done because the I.V formulation contained different dose of verapamil HCl. The absolute and relative bioavailabilities were evaluated using the following equations:
where AUC = area under the curve, b = buccal, I.V = intravenous, and VH = verapamil HCl.
Statistical analysis were performed using a Student's t test with p< 0.05 as the minimal level of significance.
Pharmacological effect of VH Induction of experimental hypertension to rabbits
Vasopressin was diluted with normal saline and given by I.V route in the marginal ear vein of the rabbit in a dose of 0.2 unit/kg daily. The ear must be well cleaned before and after the injection by ethyl alcohol.
Measurement of the mean blood pressure of induced hypertensive rabbits
The hypertensive rabbits were subdivided into three groups, three animals each. The rabbits were first anaesthetized with an intraperitoneal injection of urethane solution (25%) in a dose of 6.4 ml/kg. After shaving the neck, the trachea was canulated with a polyethylene tube. The animals were ventillated with room air. 19 Then the animals were prepared for I.V. injection of heparinized saline (1000 U/kg) through a canula placed in the right jugular vein. The rabbits of the first group were given VH 3 mg/kg (Isoptin 80, Knoll) orally by using a stomach tube. The animals of the second group were given VH 0.625 mg/kg intravenously (Isoptin ampoule, Knoll 5 mg/2 ml). The third group was given VH buccoadhesive tablet 3 mg/kg of the selected formula (F 22 ) by attaching the part of tablet to the buccal mucosa (under pouch) of rabbits by pressing it for 30 sec. During the study, the rabbit breathed normally and body temperature was maintained at 37° with the use of a heating pad. 20 The mean atrial blood pressure and pulse rate were measured from the canulated left common carotid artery which was canulated by a special canula attached to blood pressure transductor (BLP world precision instruments, INC, (WP1) USA) and an amplifier of four channels physiograph (TBN4-A, 120/240 VAC, 50/60 Hz, 20 VA, for four-channels world precision instruments, INC, (WP1) USA) which was connected to two channel recorder (Kipp and Zonen Company, PD112, Holland). The blood pressure and pulse rate were measured at suitable time intervals.
The ECG pictures of different VH formulations used
ECG is the body surface manifistation of the depolarization and repolarization waves of the heart. Cardisuny needles (Electrocardiograph, model 5010 Lead 2 AC 220 V, 50/60 Hz, 15 AV, Fukuda M.C., Kogyo Co., Ltd, Tokyo, Japan) were put subcutaneously. ECG pictures and pulse rate were measured at suitable time intervals.
RESULTS AND DISCUSSION
Buccoadhesive polymer CP974P grade was selected as it is a safer analogue of CP934P polymerized in ethyl acetate. Studies involving CP974P have indicated that it has a mild irritation effect to the buccal mucosa at higher concentration. 21 The prepared buccoadhesive tablets of VH were evaluated for physical characteristics. The results showed that all of the buccoadhesive tablets were acceptable in regard to VH content (100±4%), weight variation (Bp 1998) and friability. Tablets with crushing strengths between 1.9-10.3 kg were obtained with carbopol 974 and other polymers, hardness decreased with increasing the amounts of HPMC, SCMC, sodium alginate and guar gum. The differences in the tablet strengths were reported not to affect the release of the drug from hydrophilic matrices. 22 The drug was released by diffusion through the gel layer and/or erosion of this layer and is therefore independant of the dry state of the tablet. 22
IR spectroscopy
IR spectra of the drug, neat polymer and drug/polymers physical mixtures are presented in Figure 1 . The characteristic IR absorption peaks of VH (curve a) showed the C-H stretching vibrations of the methoxy group at 2840 cm -1 . The N-H stretching of the protonated amine group is observed in the range 2800-2300 cm -1 , and a strong absorption band due to C-O stretching of the aromatic ester group appeared at 1262 cm -1 . IR spectra of the VH/polymers (curves c, e, g, i, k, m and o) showed a prominent peak for VH at 1517 cm -1 , which is due to benzene rings. This indicates that VH is not involved in any chemical reactions with any of polymers. 
Differential scanning calorimetry (DSC)
Thermal traces of the samples under study are presented in Figure 2 . The endothermic peak of pure VH appeared at its melting point, 145° (curve a), which did not changed by the presence of any of the bioadhesive polymers. This was a further confirm of the absence of an interaction between VH and any of the polymers. 
Swelling index studies
The swelling behavior of the tablets is important in regard of bioadhesion and drug release. 23 The normalized swelling values of the matrices with CP974 and HPMC increased with increasing the amount of the first polymer. Maximum swelling was seen with formulation containing sodium alginate and PC974 ( Table  2) . The values increased with increasing amounts of sodium alginate. The normalized swelling values of tablets were in the order of F 22 > F 26 > F 25 > F 29 > F 18 > F 17 > F 1 > F 14 > F 21 . In general, it was observed that the normalized swelling values were found to be increased with increasing the concentration of the second bioadhesive polymer.
In-vitro bioadhesion study
Bioadhesion force means the force with which tablets bind to buccal mucous membranes. The bioadhesive forces of the tablets were chiefly affected by the nature and ratio of the bioadhesive polymers, since they were different in nature. [24] [25] [26] The highest detachment force was observed with formulation F 1 prepared with 65% CP974 ( Table 2 ). Increasing the content of CP974 resulted in increased detachment forces, which is in compliance with the literature. 27 
In-vitro dissolution of buccal tablets
The time course of VH release from various formulations is shown in Figures 3a-3g . The release of VH from buccoadhesive tablets varied according to the type and ratio of the polymer used. Tablets prepared using formulations F 1 to F 9 did not show any significant differences in their dissolution profiles (Figures 3a and 3b) . However, the rate of VH release from tablets containing insoluble PC974P was slower than that contained water soluble HPMC, or sodium alginate. On the other hand, the release of VH decreased with increasing concentration of carbopol 974P. This decrease in the rate of drug release may be attributed to entrappment of the drug in the core of carbopol matrix. On hydration of the surface, a gelatinous layer was formed that consisted of discrete microgels made up of many polymer particles in which the drug is dispersed. When the hydrogel was completely hydrated, it did not dissolve, but osmotic pressure worked to break up the structure, mainly by sloughing off discrete pieces of the hydrogel. The hydrogel remained intact and the drug continuously diffused through the gel layer at a more or less constant rate. It is postulated that as the concentration of the drug becomes high within the gel matrix and its thermodynamic potential increases, the gel layer around the tablet core acts as a ratecontrolling membrane, resulting in a linear release of the drug. 28 All the formulations evaluated for dissolution showed controlledrelease behavior. Almost 98% of verapamil HCl was released at the end of 6 h in formulation F 22 . 
Drug release kinetics
Drug release rates from the various formulations can be described by eq. 4, to characterize the release mechanism of VH Where M t /M ∞ is the fraction of drug release at time t, K is a kinetic constant incorporating structural and geometrical characteristics of tablets, and n is the diffusional exponent indicative of the release mechanism. 29 The value of n is 0.5 for Fickian release, i.e., the release of drug is mainly by diffusion, >0.5 and <1 for anomalous or non-Fickian release, i.e., the drug release is by diffusion as well as erosion of polymer and n= 1, for drug release that follows a zero-order mechanisms. The parameters K, n and r 2 (correlation coefficient) are listed in Table 3 . All the n values ranged between 0.575 and 0.982 indicating that the drug release is non-Fickian, i.e., the mechanism of drug release is due to polymer erosion as well as diffusion.
Based on the drug release and mucoadhesion studies, formula F 22 was chosen as buccoadhesive tablet used consequently in bioavailability studies. 
In-vivo studies
Under the condition of analytical procedure previously mentioned, the retention times of VH and diltiazem HCl were found to be 10.167 and 6.35 min, respectively ( Figure  4 ), which are appropriate times for HPLC analysis. It can be seen in Figure 4 that the peak of VH is well resoluted from that of diltiazem HCl.
The mean plasma levels profiles versus time of VH obtained after buccal dosing of formulation F 22 is shown in Figure 5 . For comparative purpose, the plasma concentration-time profile after oral and intravenous administration of VH is also shown. Absorption of VH from buccoadhesive tablets was much slower and extended over a longer period of time compared with oral and intravenous VH. The plasma concentration curves for buccoadhesive tablet showed evidence of a more sustained release of VH. The pharmacokinetic parameters derived from these plasma concentration-time curves are given in Table 4 . The bioavailability of VH calculated from the ratio AUC [(oral or buccal / i.v.) x 100] was 46.95% for buccoadhesive tablet, which compares favourably with a value 24.81% calculated for oral bioavailability. These observations clearly indicate that the bioavailability of VH from buccoadhesive tablet is significantly improved (approximately two fold) over the bioavailability observed after oral administration of drug solution. This is attributed to avoidance of the first-pass metabolism through the buccal route. Further delayed T max and C max values from the buccoadhesive tablets compared to drug solution and maintainance of higher blood levels until the last sample from the buccoadhesive tablet than for the drug solution clearly indicate that the buccoadhesive dosage form not only improved the bioavailability of the drug VH, but also gave prolonged and controlled blood level profiles of VH. Table 5 summarizes the effect of VH from the tested preparations on the blood pressure of induced hypertensive rabbits. Data in Table 5 showed that, the reduction in blood pressure after drug suspension administered orally, began after 30 min (140±7.5 mmHg) and continued for 4 h. A maximal antihypertensive effect was reached at around 2 hr (103±6.3 mmHg). Results of commercially available intravenous VH (0.625 mg/kg) revealed that, the antihypertensive effects on blood pressure of hypertensive rabbits occurred just after administration and reached a maximum effect after 15 min (69±4.3 mmHg). This effect in blood pressure remained for 5 h. In case of buccoadhesive tablet (3 mg/kg), the results show that, the antihypertensive effect on blood pressure of hypertensive rabbits was significantly observed after 15 min (120±5.4 mmHg) and reached its maximum effect at around 4 h (63±4.8) and continued until last sample. Normal systolic blood pressure of rabbits is 90 mmHg. Table 6 shows the effect of plasma concentration of VH on the pharmacological response (blood pressure and heart rate), where VH has a direct relationship between plasma concentration and pharmacological response. 30 The pharmacological results obtained, clearly indicated that the administration of buccoadhesive tablet led to a significant prolongation and improvement of the antihypertensive effect compared with the oral administration of VH suspension. This increased bioavailability of VH from the buccoadhesive tablet might be due to the potential avoidance of first-pass hepatic metabolism. Considering that the absolute bioavailability of the buccal tablets is greater than the oral VH suspension, a lower dose of VH may be used in VH therapy. This could reduce the various side effects of VH associated with the usual higher clinical doses (Isoptin 80, 120, or 240 mg tablets) of the drug.
Pharmacological activity Effect of VH in different dosage forms on mean blood pressure of induced hypertensive rabbits
Relationship between plasma concentration of VH and the pharmacological response after buccal administration to rabbits at dose of 3 mg/kg
Conclusion
The present investigation established the usefulness of buccoadhesive tablets as potential controlled and prolonged -release formulation of VH. Beside the buccal administration showed a significant improvement of bioavailability of VH compared to that achieved by oral administration. Furthermore, the plasma concentration-time curve for buccoadhesive tablets showed evidence of sustained-release of drug (T max of 4 h for buccoadhesive tablet compared to 2 h for oral administration). The buccal tablets were of satisfactory hardness and showed good bioadhesion to bovine mucosal membrane.
